Movement Disorders

Patients with Parkinson disease experiencing “off” episodes on levodopa/carbidopa now have another treatment option.

April news includes tools to manage brain injury and predict recovery, new drug hits and misses, and an updated epilepsy classification system.

How frequently are your patients with Parkinson disease reporting pain and is that pain effectively managed?

March news includes possible brain tumor therapies, a study exploring mechanisms underlying demyelination-induced seizures, and VNS post stroke.

Did patients with advanced Parkinson disease switched to extended release carbidopa-levodopa experience clinical benefits?

Studies also include stem cell transplantation for treatment-refractory MS and aspirin use for headache to lessen the need for rescue medication.

Ten general and disease-specific apps for neurologists include assessment scales, anatomical diagrams, and interactive clinical decision support.

Is the parkinsonian phenotype seen in welders related to the exposure of manganese-containing welding fumes?

February news includes stroke risk with Alzheimer disease & migraine, neonatal hemorrhagic stroke, and head trauma in sports.

A phase 3 trial examined the safety and effectiveness of adjunctive opicapone in patients with Parkinson disease treated with levopoda.

Can we see changes in the brain that correspond to cognitive difficulties? Research presented at AAN 2016 offers compelling information.

January news includes the first FDA-approved drug for spinal muscular atrophy, various epilepsy treatments & vitamin D’s impact on Alzheimer & headache.

Orthostatic hypotension’s effect on cognition in Parkinson disease, testing patients with epilepsy who can drive safely, and carotid web are covered.

From Alzheimer disease to Zika virus, we’ve compiled a list of this year’s most popular articles on Neurology Times.

Ground-breaking research suggests that the gut microbiome may play a role in the pathogenesis of Parkinson disease.

November news includes the first human clinical trial focusing on tau in Alzheimer disease and Zika-related microcephaly not presenting at birth.

November news includes potential Alzheimer treatments, FDA approval of a device to prevent recurrent stroke, & a newly typified headache disorder.

Data blitz presentations at ANA 2016 featured studies on neuronal dysfunction and degeneration in ALS, Parkinson disease, transverse myelitis, & more.

Oct. news includes an approved deep brain stimulation system for movement disorders & biomarkers that improve risk assessment in atrial fibrillation.

Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.

Our August news includes a potential classification system for Alzheimer disease, new findings in a 3D model of TBI, and migraine treatments.

A study of 30 years indicates the projected increase in Parkinson disease could be underestimated and offers possible explanations.

Recent neurological studies outline a link between TBI and Parkinson disease, discuss neuroimaging to predict recovery, and warn against DIY tDCS.

Our July news includes the Alzheimer-diabetes link, increased rates of Parkinson, and guidelines for acute migraine treatment in the ED.

Nuplazid, which the FDA designated as a breakthrough therapy and granted priority review, could help approximately 50% of Parkinson patients.